Disc Medicine, Inc. (IRON) Phase 3 Bitopertin Met All Endpoints

Disc Medicine (IRON) priced a $450M offering of 6M shares at $75/shr, with a 30-day option for 0.9M more. Proceeds will fund pipeline development, including Bitopertin for EPP and XLP. IRON closed at $79.48, down 0.79% overnight. Jefferies, Leerink, Morgan Stanley, and others are underwriters.

Disc Medicine Inc. (IRON) priced a 6M share offering at $75/share, raising $450M gross. Underwriters have a 30-day option for 900K more shares. Proceeds will fund R&D, commercialization, and working capital. The offering is expected to close Friday. Joint book-runners include Jefferies, Leerink, Morgan Stanley, and Cantor.

Disc Medicine, Inc. (IRON) priced a $450M stock offering at $75 per share, selling 6M shares with an option for 900,000 more. Closing is expected Oct. 22, 2026, subject to conditions. According to the company, proceeds will support potential commercialization efforts.

Disc Medicine (NASDAQ: IRON) plans to raise $450 million from selling 6 million shares at $75 each. The company will use the funds for research, clinical development, and potential commercialization of treatments, including bitopertin for EPP and XLP. The offering is managed by several underwriters and follows a previously filed registration statement.

Disc Medicine's Phase 3 trial for a rare light-sensitivity disorder met all endpoints, shares rose 38.86%. Silence Therapeutics agreed to a $1.3B acquisition by Merck KGaA at a 130% premium, shares up 125.58%. Other rare blood disorder-focused companies also saw gains. Disc plans FDA resubmission by 2026 end, Silence deal expected Q1 2027.

Cantor Fitzgerald raised its price target for Disc Medicine (IRON) to $170 from $125, citing positive Phase 3 trial data for bitopertin. The stock surged 39% last week to $78.93, with a market valuation of $3.03B. Analysts maintain a Strong Buy consensus, with targets ranging from $86 to $170. Disc Medicine plans to resubmit its New Drug Application by year-end.